More Than Machine: Intelligent Robotics and Implants Are Rewiring Health Tech

Part 8 of Talencio’s Series, “Navigating 2026: The Top 10 Health Technology Trends Every Leader Should Watch”

For the last 30 years, the defining value of many surgical technologies was largely mechanical. Devices were used to cut, visualize, stimulate, replace, or repair.

That definition is rapidly changing as yesterday’s science fiction becomes today’s science reality.

Surgical robots and implantable devices are becoming intelligent, connected and constantly evolving platforms. They combine precision hardware with embedded artificial intelligence, real-time data, software updates, remote services and increasingly personalized functionality. The physical structure remains essential, but it is no longer the entire product.

Commercial momentum is becoming difficult to dismiss. The surgical-robot market reached an estimated $15.85 billion in 2025 and is projected to grow nearly 16% annually through 2034.¹

Meanwhile, Intuitive Surgical’s well-known da Vinci procedure volume — a benchmark of the category’s traction — increased 68% per annum between 2022 and 2025.² Intelligent implant categories, while smaller, are also expanding rapidly, with neuromodulation projected to more than double between 2025 and 2033.³

Innovation is also surging as Johnson & Johnson, Medtronic, Intuitive Surgical, Neuralink, and other players expand across soft-tissue, orthopedic, microsurgical, and specialty procedures.^4,5 Many manufacturers are introducing real-time software, AI, and therapeutic capabilities that can extend the value of robotic platforms long after installation.^6,7Implantable systems are becoming more sophisticated, too, increasingly using signals from the body to monitor patients and personalize therapy.⁵

For health technology executives, all of these data points is more than an interesting trend. It fundamentally changes how their companies create value, generate revenue, organize teams, and build and maintain marketplace trust.

Here are some specific trends that can be seen in this corner of health care:

Hardware is becoming a platform

Health technology businesses have conventionally organized themselves around a familiar sequence: develop the product, test and tweak, secure regulatory approval, launch and then support the installed base.

Today, a platform may receive new instruments, algorithms, workflow applications, and training capabilities through successive releases. A connected implant may generate longitudinal data, support remote monitoring or adjust therapy in response to physiological signals. Commercial launch therefore becomes the beginning of a long product lifecycle, not the culmination of development.

Software can be offered through subscriptions, with varying levels of analytics, decision support and deeper integration into clinical workflows⁶, but this poses interesting choices and opportunities. Most health technology manufacturers welcome the opportunity to generate value throughout the life of a platform rather than primarily at the point of sale. But they’ll need to win over some audiences and sustain software development, validation, cybersecurity, compatibility, and customer support across multiple hardware generations.

Product roadmaps must account for what will be updated, what will remain backward-compatible and what will require additional regulatory review.

AI is moving closer to the procedure

Until recently, health care AI primarily made its mark before or after an intervention. It helped clinicians plan procedures, review images or analyze outcomes. It helped hospitalists take faster notes and improve workflows. It helped computational biologists crunch drug discovery data, and labs improve their pathology results, among other uses.

In 2026, AI has been moving closer and closer to the live procedure.

Medtronic recently introduced Touch Surgery Aide, an intraoperative computing platform designed to process video and procedural information in real time. Its first FDA-cleared application alerts surgical teams when instruments move beyond the visible field during a robotic procedure.⁶ Intuitive Surgical is also expanding AI, telepresence, and digitally delivered capabilities across its robotic ecosystem.⁷

These early applications may appear modest compared with fully autonomous surgery, but they represent a significant transition. Robotics is advancing from technology that primarily translates a surgeon’s movements to technology that can interpret the procedural environment and assist in the moment.⁸

The near-term opportunity is likely to be augmented surgery, not autonomous surgery. AI can help recognize anatomy, monitor instrument movement, identify workflow deviations, retrieve relevant information, or support consistency. The clinician remains responsible, but the system becomes a more active participant, not unlike the “umpire assist” systems recently integrated into professional baseball.

For executives, this raises strategic questions:

Which applications solve important clinical or operational problems?
Is the algorithm integral to the device or an optional software layer?
How will its performance be monitored after deployment?
What evidence will persuade surgeons and health systems to trust it?
Who is accountable when software influences a procedural decision?

Adding AI is not merely a technical exercise. It requires coordinated leadership, candid communication and regular feedback across clinical affairs, regulatory, quality, engineering, cybersecurity and commercialization.

Technology is making procedures increasingly remote

It’s not just that today’s procedures can be robot-assisted. They can also stretch across cities, counties and even continents—and are already used for time-sensitive interventions.⁹

In March 2026, XCath reported the first remote robotic intervention in a living stroke patient. A neurosurgeon in Santiago, Panama used the company’s Iris robotic system to perform a mechanical thrombectomy on a patient more than 120 miles away in Panama City. Operating from a remote console, the surgeon navigated catheters through the patient’s blood vessels and removed a large clot from the brain on the first attempt, with no perceptible lag reported. The patient showed significant neurological improvement within 24 hours.¹⁰

The example is especially meaningful because successful stroke treatment is extraordinarily time sensitive. Yet the specialists capable of performing mechanical thrombectomies are concentrated in relatively few advanced stroke centers. Telerobotic systems could eventually bring the specialist to the patient virtually, reducing the need to transport critically ill patients over long distances and potentially preserving precious treatment time.

Remote procedures are only one part of the opportunity. Teleproctoring and remote observation, mentoring, and specialist support technologies can help organizations train clinicians, introduce new procedures, and extend expertise across borders and throughout hospital networks. They can plug expert knowledge into situations involving uncommon or time-sensitive needs and mitigate geographic disparities and workforce constraints that plague rural and remote areas

The momentum of telesurgery will depend on multiple factors. Health systems and their manufacturer partners must address network speed and reliability, latency, cybersecurity, emergency protocols, as well as a host of human issues like credentialing, licensing, and liability.

There is much to resolve, but the trajectory feels increasingly inevitable in a connected and digital age. Leaders who understand both the technology and the care-delivery environment in which it operates will be highly sought after.

The site of the care is changing the product

Here’s a layer of medical robotics disruption that may be somewhat unexpected: the growth of ambulatory surgery centers.

Robotic platforms have traditionally been designed for large hospital ORs with substantial capital budgets, specialized staff and high procedure volumes. However, newer upstarts have found they can successfully target outpatient facilities with solutions that are smaller, more mobile, and better suited to existing workflows.¹¹

The economics are compelling. An April 2026 analysis released by the Ambulatory Surgery Center Association estimated that ASCs save Medicare more than $5 billion annually compared with hospital outpatient departments.¹²

Yet a robot designed for a major medical center may not translate seamlessly into that setting. ASCs place a premium on rapid turnover, predictable costs, limited space, simplified sterilization and efficient staffing.

Health technology executives should resist viewing site-of-care migration as only a sales-channel opportunity. It may require a different product architecture, service model, pricing strategy and customer value proposition.

The winning platform may not be the one with the most features. It may be the one that brings the least amount of operational friction to the clinical setting.

New value opportunities emerge — with new obligations

As devices become platforms, revenue models are expanding beyond capital equipment and implants.

Software subscriptions, analytics, maintenance, disposable instruments, remote services, and procedure-based fees can create new revenue streams and increase customer lifetime value. But stakeholders will not necessarily pay more or consent to new components of care simply because they’re digital or AI-enabled.

Manufacturers must demonstrate what each layer of their technology accomplishes, such as:

Reducing procedure time
Expanding capacity
Improving accuracy
Shortening recovery
Preventing complications
Reducing staff requirements
Enabling procedures to move into lower-cost settings

Different stakeholders will have different hot buttons. A surgeon may value control and consistency. A hospital may prioritize throughput, utilization, and total cost. An ASC may focus on room turnover and per-procedure economics. A payer may require evidence of better outcomes or avoided downstream expenses.

Moreover, a connected robot or implant can provide many exciting benefits, but it can also introduce vulnerabilities related to patient information, clinical operations, and device performance. FDA cybersecurity materials emphasize that connected devices operate as components of larger systems that include hospital networks, other devices, and update servers.¹³

Health tech companies with evolving yet enduring business models need to identify vulnerabilities, deploy secure updates, manage access, communicate with customers, and respond rapidly when threats emerge. They must also establish clear principles for data ownership, consent, interoperability and secondary use. They may be able to collect an extraordinary amount of information, but every use of that information will not be acceptable to patients, clinicians, or health systems.

The challenge isn’t simply to create sophisticated technology and new ways to offer value and generate revenue. It’s to connect that technology to safe, measurable outcomes that are understood and appreciated by key stakeholders.

Implications for talent

The most significant leadership implication is organizational.

The next generation of surgical and implantable technologies requires workforce capabilities that many traditional device organizations haven’t historically needed at scale: cloud architecture, AI development, data governance, software quality, cybersecurity, and more advanced human factors engineering, to name a few.

Health technology companies should consider whether they have:

Product leaders who can manage hardware and software as one roadmap
Regulatory and quality professionals comfortable with iterative development
Clinical leaders who can translate workflow problems into useful applications
Cybersecurity experts with authority to influence product decisions
Commercial talent capable of selling economic and operational value
Executives able to build partnerships across hospitals, tech firms, networks, and data
ecosystems

The key is not merely finding more technical specialists. It is identifying leaders who can integrate disciplines that have historically operated separately and build teams that translate technical know-how into clinical, regulatory, and commercial value.

Success depends on cross-functional transformation, frontline participation and fluency across leadership levels, while keeping patient safety and customer needs at the center.¹⁴

The leadership mandate

Surgical robots and implants are becoming less passive, but that doesn’t make the hardware less important. It makes the business surrounding the hardware far more consequential.

The companies best positioned for success will understand that the product is no longer just a machine or an implant. It’s a vessel of technology, evidence, services, data and relationships.

For executives navigating 2026, the mandate is clear: build for continuous value, prove the economic and clinical case, protect trust, and assemble teams capable of connecting specialized disciplines.

The device may open the door. The ecosystem — and the people behind it — will determine who stays in the room.

Sources

About the Author

Paula Norbom is the Founder and CEO of Talencio, an executive search and staffing firm serving health technology companies. She has worked in the health technology industry for over 30 years.

More Than Machine: Intelligent Robotics and Implants Are Rewiring Health Tech

Part 8 of Talencio’s Series, “Navigating 2026: The Top 10 Health Technology Trends Every Leader Should Watch”

Recent Posts

Categories

Archives